NLSP — NLS Pharmaceutics AG Cashflow Statement
0.000.00%
Last trade - 00:00- $8.38m
- $9.46m
Annual cashflow statement for NLS Pharmaceutics AG, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -2.86 | -11.9 | -16.5 | -12.2 | -1.98 |
| Depreciation | |||||
| Non-Cash Items | 0.068 | 0.167 | 0.978 | 0.224 | -2.37 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.06 | -3.17 | 1.63 | 2.25 | 0.078 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -0.729 | -14.9 | -13.9 | -9.68 | -4.27 |
| Capital Expenditures | — | -0.04 | 0 | 0 | -0.004 |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | — | -0.04 | 0 | 0 | -0.004 |
| Financing Cash Flow Items | -0.687 | 0 | 0 | — | -0.386 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.504 | 20.3 | 17.4 | 1.63 | 5.04 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.127 | 5.34 | 3.52 | -8.05 | 0.768 |